Overview

An Efficacy and Safety Study of Abiraterone Acetate and Prednisone in Participants With Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

Status:
Completed

Trial end date:
2011-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of abiraterone acetate in participants with advanced prostate cancer (a disease in which cells in the prostate gland become abnormal and start to grow uncontrollably, forming tumors).

Phase:

Phase 2

Details

Lead Sponsor:

Cougar Biotechnology, Inc.

Treatments:

Abiraterone Acetate
Androgens
Docetaxel
Prednisone